Barclays Maintains an 'Overweight' on Halozyme Therapeutics (HALO); Underappreciated Assets Plus Possible Partnership On Deck

Go back to Barclays Maintains an 'Overweight' on Halozyme Therapeutics (HALO); Underappreciated Assets Plus Possible Partnership On Deck